<DOC>
	<DOCNO>NCT00006630</DOCNO>
	<brief_summary>The purpose study follow response treatment vaccinia immune globulin ( VIG ) safety clinical benefit [ HIV vaccine research ] . VIG purify human blood use treat serious infection vaccinia ( smallpox vaccine ) virus similar virus . It treatment available virus . The available supply VIG develop discoloration time therefore consider investigational new drug FDA . This study allow use intramuscular injection control set people may need [ HIV vaccine research ] .</brief_summary>
	<brief_title>Vaccinia Immune Globulin Treating Preventing Vaccinal Infection</brief_title>
	<detailed_description>VIG ( Human ) component plasma person vaccinate vaccinia vaccine . It product available treatment vaccinia orthopox infection . The lot currently available release licensed product 1995 treat investigational new drug slight discoloration solution . This study make exist stock VIG available short-term solution lack license immune globulin treat vaccinal infection . Before receive injection 3 6 month injection , patient test HIV , hepatitis B , hepatitis C pre- post-test counseling . Referrals appropriate medical care provide . Participants multiple injection ( depend body weight ) VIG 1 2 clinic visit . Following administration VIG , participant observe 1/2 hour clinic . Participants return clinic many 10 visit monitor adverse reaction sign symptom vaccinia infection . On Days 7 , 84 , 168 participant return clinic evaluation blood drawn check response VIG injection .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Inclusion Criteria Participants may eligible study : Sign consent form include consent pre/post HIV counseling . If 18 year unable sign consent form , next kin legal guardian must sign . Experience complication prior administration vaccinia virus vaccination accidental exposure vaccinia similar virus . Have pregnancy test . Exclusion Criteria Participants eligible study : Have eye complication . Note : Caution note participant allergic thimerosal ( preservative study drug ) . Precautions take participant experience reaction VIG administration . Women pregnant counsel risk .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Smallpox Vaccine</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Orthopoxvirus</keyword>
</DOC>